Researchers discovered a DNA repeat expansion in GOLGA8A associated with many cases of a rare frontotemporal dementia. The ...

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms, characterized by muscle wasting, paralysis, dementia ...

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms ...

Girl Scouts of Eastern Pennsylvania Troop 902 in Fishtown needs to sell at least 4,000 more boxes of cookies by March 22 to fund their programs and avoid possible shutdown.

GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from ...

Alector, Inc. (ALEC) pivots to its Alector Brain Carrier (ABC) platform, focusing on enhanced blood-brain barrier delivery ...

Materials Select Sector SPDR ETF (XLB) holds 94.4% in materials. Linde dominates at 13.42% of the portfolio. XLB delivered strong double-digit returns over the past year driven by infrastructure ...

Scientists at Rice University and the University of Houston have created a powerful new material by guiding bacteria to grow cellulose in aligned patterns, resulting in sheets with the strength of ...

CEO Christopher Missling presented an update on the company’s central nervous system pipeline at the firm’s 46th Annual Healthcare Conference, highlighting late-stage data for its oral Alzheimer’s ...

Yusuke Tsukahara , Corporate Strategy Officer, and Nobuo Takeda, Chief Operating Officer, and both C-Founders at Ball Wave, explain how the company’s ball SAW sensor technology represents a ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid ...